D
espite centuries of research into the cause of venous thrombosis and the availability of effective anticoagulants for >50 years, deep venous thrombosis (DVT) remains a major health problem with an annual estimated incidence of 45 to 117 per 100 000 person-years and high rates of recurrence. 1 The postthrombotic syndrome (PTS) is a chronic and common complication of DVT, affecting almost half of all patients diagnosed with DVT. 2 PTS remains an incompletely understood phenomenon but is believed to be the result of a complex interplay of obstruction of venous outflow with acute DVT despite varying degrees of endogenous recanalization, the inflammatory response to thrombosis, and damage to venous valves with resultant valvular reflux. The combination of these factors results in lower extremity venous hypertension, which causes the physical manifestations of PTS, including calf muscle dysfunction, edema, subcutaneous fibrosis, tissue hypoxia, and ulceration. 3 The syndrome may lead to marked disability, significantly reduced quality of life, and considerable associated healthcare costs. 4, 5 Symptoms progress over time after the initial diagnosis in a significant proportion of patients despite conservative therapies. 6 Anticoagulation remains the current standard of care for DVT, with therapy preventing the extension of existing thromboses and reducing the risk of further venous thromboembolism. Limiting the expansion of acute DVT with anticoagulation provides intrinsic mechanisms of fibrinolysis with the opportunity to recanalize thrombosed venous segments. Because capillary leak is a necessary mediator of tissue edema as a result of venous hypertension, elastic compression stockings remain a widely used therapy after DVT for the prevention of PTS. Early studies suggested a 50% reduction in the incidence of PTS after the diagnosis of iliofemoral DVT with the use of elastic compression stockings. 1 However, elastic compression stockings are poorly tolerated by many patients, and a recent large, randomized, placebo-controlled trial demonstrated no benefit to the routine use of elastic compression stockings after iliofemoral DVT for the prevention of PTS. 7 Similarly, although exercise has been postulated to improve PTS after DVT, prospective studies of exercise have demonstrated little to no benefit. 8 
ACTIVE TREATMENTS FOR PREVENTION OF POSTTHROMBOTIC SYNDROME
The advent of catheter-based therapies and synthetic thrombolytics has allowed physicians to assume a more active role in the treatment of DVT. Proponents of thrombolytic and catheter-based therapies are adherents of the open-vein hypothesis, whereby early and active removal of thrombus may improve deep venous flow and reduce venous reflux. The hypothesis is particularly invoked with iliofemoral DVTs, which are associated with lower recanalization rates when treated with anticoagulation alone. 9 Until recently, the largest clinical trial of catheter-directed thrombolytic (CDT) therapy for the treatment of acute DVT to prevent PTS was the CaVenT (CatheterDirected Thrombolysis versus Standard Treatment for Acute Iliofemoral Deep Vein Thrombosis) trial, published in 2012. 10 In this open-label, randomized, controlled trial, 209 patients with acute iliofemoral DVT from 20 hospitals in Norway were randomly assigned to conventional treatment with anticoagulation or CDT. The CDT procedure in this trial involved placement of an infusion catheter into the thrombosed segment with alteplase delivery over a period of up to 96 hours and operator discretion regarding the use of any adjunctive mechanical therapies to recanalize the vein. After 24 months of follow-up, CDT resulted in improved iliofemoral patency (65.9% versus 47.4%; P=0.012), and a lower rate of PTS, defined as either a Villalta score of ≥5, or the presence of a venous ulcer (41.1% versus 55.6%; P=0.047). These findings were persistent at 5-year follow-up, generating considerable interest in the open-vein hypothesis and treatment of iliofemoral DVT with CDT. 11 To further address this issue with modern interventional techniques in a larger US sample, the ATTRACT (Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis) study randomly assigned 692 patients with acute proximal DVTs (femoral, common femoral, or iliac veins) from 56 clinical centers to therapy with anticoagulation alone versus CDT. 12 The CDT procedure in this trial involved catheter-mediated intrathrombus delivery of alteplase in conjunction with several mechanical recanalization techniques, including rheolytic thrombectomy, maceration, angioplasty, and venous stenting used at the operator's discretion. In contrast to the results of the CaVenT trial, between 6 and 24 months of follow-up, there was no significant difference in the percentage of patients who developed postthrombotic syndrome at any time point, defined as either a Villalta score of ≥5, or the presence of a venous ulcer (47% versus 48%; P=0.56). Secondary end points of moderate-to-severe PTS were less common with CDT (18% versus 24%; P=0.04), and severity scores for PTS were lower at each time point of analysis (P<0.01 for comparison of Villalta scores).
Because iliofemoral DVT is a particularly high risk for the development of PTS, in this issue of Circulation, Comerota et al 13 present the results of a prespecified substudy of the ATTRACT trial, studying CDT in patients with iliofemoral DVT. Of the 692 patients in the ATTRACT trial, 57% had iliofemoral DVT, resulting in 391 patients in the current analysis. Similar to the findings of the main ATTRACT trial, this substudy found no difference in the incidence of PTS between 6 and 24 months when comparing anticoagulation alone with CDT with pharmacomechanical thrombolysis. However, secondary end points of mean PTS severity, incidence of moderate-to-severe PTS (18% versus 28%; P=0.021), and severe PTS (8.7% versus 15%; P=0.048) were lower with CDT. It is important to note that, whereas the negative primary end point finding closely mirrored that of the full study, the current substudy results indicate that benefits in reported secondary end points appear to be driven by the iliofemoral subgroup. These findings are hypothesis generating and, as the authors properly state, not definitive.
DIFFERENCES BETWEEN CAVENT AND ATTRACT
Despite successful thrombolysis of the iliofemoral venous system in both CaVenT and the ATTRACT substudy, the results of the 2 studies were markedly different, with a 14% absolute risk reduction of PTS with CDT in the former and no significant benefit of CDT in the latter. This occurred despite the fact that the primary end point of ATTRACT was designed to favor a positive result. Although both CaVenT and ATTRACT defined PTS as a Villalta score of ≥5 or the presence of an ulcer, the coprimary end point of CaVenT assessed for this at the 24-month follow-up visit, whereas ATTRACT reassessed for the presence of PTS at each time point between 6 and 24 months (6, 12, 18, or 24 months). In other words, in ATTRACT, you could qualify as achieving the PTS primary end point at any of 4 follow-up visits regardless of whether your symptoms improved at subsequent visits. It is notable that the same end point assignment structure holds for the positive finding of moderate-to-severe PTS among patients with iliofemoral DVT in ATTRACT, significantly muddying the interpretation of this finding in the current AT-TRACT subanalysis. So, the question remains: Why was CaVenT a positive study and ATTRACT a negative study even with the deck stacked in favor of ATTRACT?
One possibility is that the combination of chance and small sample size played a role in the CaVenT results. Indeed, although 24-month PTS in CaVenT was lower in patients treated with CDT, the confidence intervals for this end point in the CDT and anticoagulation groups actually overlapped, signaling that there was a significant chance that these groups were not really as different as indicated by their point estimates. The implication here is that ATTRACT, a much larger trial, simply allowed for a more accurate estimate of the true effect of CDT in patients with acute DVT.
But another nonstatistical possibility might also have played an important role. In CaVenT, the majority of patients underwent isolated thrombolytic infusion with only ≈40% undergoing mechanical treatments for DVT in addition to lysis. However, only 6% of patients in the current iliofemoral ATTRACT substudy, and 12% of AT-TRACT patients overall, underwent isolated thrombolysis.
NOT ALL OPEN VEINS ARE EQUAL
The aggressive catheter therapies used in the ATTRACT study generally result in open veins. However, we do not know what the consequences of these mechanical therapies are for venous valves. Rheolytic thrombectomy, angioplasty, and stenting are highly likely to damage these delicate valves. Future PTS studies should not focus solely on patency, but also consider venous reflux, venous capacity, and the importance of venous valves. The signal from these trials that more aggressive mechanical therapies may have a downside in comparison with a simple isolated thrombolytic infusion catheter also has significant implications for the growing interest in single-session acute venous recanalization therapy. 14 Despite the convenience of this approach for the patient and the efficiencies created for the health system, it is unclear whether such an approach will result in optimal long-term outcomes.
In the wake of ATTRACT, catheter-based therapy for acute DVT will continue to have a role for patients with severe symptoms (including those with phlegmasia cerulea dolens) and low bleeding risk. Many interventionalists will take solace in the host of secondary end points clearly demonstrating more rapid symptomatic improvement in patients treated with CDT, in particular those with iliofemoral disease. However, if our true goal is long-term PTS prevention and not just early symptom improvement, our aim going forward should perhaps be less concentrated on acutely opening veins and more focused on chronically preserving valves.
